UG · United-Guardian, Inc.

United-Guardian delivered strong Q1 2026 results with net sales up 16% to $2.87 million, fueled by robust growth in both pharmaceuticals (24% increase, led by Renacidin demand) and cosmetic ingredients (21% rise, driven by 45% higher purchases from key distributor Ashland Specialty Ingredients after they cleared excess inventory from 2025). Gross margins expanded as cost of sales rose less proportionally, contributing to operating income growth to $642 thousand from $611 thousand. Net income surged 46% to $819 thousand ($0.18 per share) versus $561 thousand ($0.12 per share), significantly aided by $303 thousand settlement income from a Renacidin contract manufacturer's 2023 shutdown, alongside other income of $391 thousand including investment gains. President Donna Vigilante highlighted normalized ASI purchasing, new distribution agreements, expansion of 'natural' product lines, and intensified Renacidin marketing as catalysts for continued 2026 sales momentum, signaling sustained top-line growth potential without providing specific numerical guidance.